{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T01:28:11Z","timestamp":1786584491223,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-75132-3","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:36:30Z","timestamp":1783172190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CAF-derived PAI-1 serves as an EGFR ligand and fuels KRAS-mutant pancreatic cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunjin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0150-1343","authenticated-orcid":false,"given":"Tianxing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6062-7556","authenticated-orcid":false,"given":"Yuh-Pyng","family":"Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3971-9130","authenticated-orcid":false,"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1967-3593","authenticated-orcid":false,"given":"Xuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4317-4740","authenticated-orcid":false,"given":"Mien-Chie","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3066-5209","authenticated-orcid":false,"given":"Yu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1607-1730","authenticated-orcid":false,"given":"Jihui","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"75132_CR1","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1056\/NEJMra0707704","volume":"358","author":"F Ciardiello","year":"2008","unstructured":"Ciardiello, F. & Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160\u20131174 (2008).","journal-title":"N. Engl. J. Med."},{"key":"75132_CR2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","volume":"25","author":"CL Arteaga","year":"2014","unstructured":"Arteaga, C. L. & Engelman, J. A. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25, 282\u2013303 (2014).","journal-title":"Cancer Cell"},{"key":"75132_CR3","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken, J. B. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359, 1116\u20131127 (2008).","journal-title":"N. Engl. J. Med."},{"key":"75132_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1200\/JCO.23.02075","volume":"43","author":"H Sun","year":"2025","unstructured":"Sun, H. et al. Thoracic radiotherapy improves the survival in patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors: a multicenter, randomized, controlled, phase III trial. J. Clin. Oncol. 43, 412\u2013421 (2025).","journal-title":"J. Clin. Oncol."},{"key":"75132_CR5","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1001\/jama.2016.4324","volume":"315","author":"P Hammel","year":"2016","unstructured":"Hammel, P. et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. Jama 315, 1844\u20131853 (2016).","journal-title":"Jama"},{"key":"75132_CR6","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960\u20131966 (2007).","journal-title":"J. Clin. Oncol."},{"key":"75132_CR7","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1200\/JCO.2017.72.6463","volume":"35","author":"M Sinn","year":"2017","unstructured":"Sinn, M. et al. CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after r0 resection of pancreatic cancer: a multicenter randomized phase III trial. J. Clin. Oncol. 35, 3330\u20133337 (2017).","journal-title":"J. Clin. Oncol."},{"key":"75132_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.ccell.2018.02.012","volume":"33","author":"YN Wang","year":"2018","unstructured":"Wang, Y. N. et al. Angiogenin\/ribonuclease 5 is an EGFR ligand and a serum biomarker for erlotinib sensitivity in pancreatic cancer. Cancer Cell 33, 752\u2013769.e758 (2018).","journal-title":"Cancer Cell"},{"key":"75132_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41392-020-00251-2","volume":"5","author":"N Yao","year":"2020","unstructured":"Yao, N. et al. Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth. Signal Transduct. Target Ther. 5, 214 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"75132_CR10","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.cell.2017.09.017","volume":"171","author":"DM Freed","year":"2017","unstructured":"Freed, D. M. et al. EGFR ligands differentially stabilize receptor dimers to specify signaling kinetics. Cell 171, 683\u2013695.e618 (2017).","journal-title":"Cell"},{"key":"75132_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nrm3048","volume":"12","author":"R Avraham","year":"2011","unstructured":"Avraham, R. & Yarden, Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol. 12, 104\u2013117 (2011).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"75132_CR12","doi-asserted-by":"crossref","unstructured":"Varghese, A. M. et al. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Nat. Med. 31, 466\u2013477 (2025).","DOI":"10.1038\/s41591-024-03362-3"},{"key":"75132_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-024-01634-6","volume":"18","author":"A Glaviano","year":"2025","unstructured":"Glaviano, A. et al. Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition. J. Hematol. Oncol. 18, 6 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"75132_CR14","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1158\/2159-8290.CD-19-1353","volume":"10","author":"E Helms","year":"2020","unstructured":"Helms, E., Onate, M. K. & Sherman, M. H. Fibroblast heterogeneity in the pancreatic tumor microenvironment. Cancer Discov. 10, 648\u2013656 (2020).","journal-title":"Cancer Discov."},{"key":"75132_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.molmed.2023.03.002","volume":"29","author":"R Rebelo","year":"2023","unstructured":"Rebelo, R., Xavier, C. P. R., Giovannetti, E. & Vasconcelos, M. H. Fibroblasts in pancreatic cancer: molecular and clinical perspectives. Trends Mol. Med. 29, 439\u2013453 (2023).","journal-title":"Trends Mol. Med."},{"key":"75132_CR16","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/2159-8290.CD-23-0426","volume":"14","author":"J Ye","year":"2024","unstructured":"Ye, J. et al. Senescent CAFs mediate immunosuppression and drive breast cancer progression. Cancer Discov. 14, 1302\u20131323 (2024).","journal-title":"Cancer Discov."},{"key":"75132_CR17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41575-019-0115-0","volume":"16","author":"H Kobayashi","year":"2019","unstructured":"Kobayashi, H. et al. Cancer-associated fibroblasts in gastrointestinal cancer. Nat. Rev. Gastroenterol. Hepatol. 16, 282\u2013295 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"75132_CR18","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","volume":"39","author":"S Affo","year":"2021","unstructured":"Affo, S. et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell 39, 866\u2013882.e811 (2021).","journal-title":"Cancer Cell"},{"key":"75132_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/s43018-022-00426-6","volume":"3","author":"M Yuan","year":"2022","unstructured":"Yuan, M. et al. Cancer-associated fibroblasts employ NUFIP1-dependent autophagy to secrete nucleosides and support pancreatic tumor growth. Nat. Cancer 3, 945\u2013960 (2022).","journal-title":"Nat. Cancer"},{"key":"75132_CR20","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ccell.2022.04.011","volume":"40","author":"H Huang","year":"2022","unstructured":"Huang, H. et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell 40, 656\u2013673.e657 (2022).","journal-title":"Cancer Cell"},{"key":"75132_CR21","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1038\/s41588-024-01890-9","volume":"56","author":"C Shiau","year":"2024","unstructured":"Shiau, C. et al. Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment. Nat. Genet. 56, 2466\u20132478 (2024).","journal-title":"Nat. Genet."},{"key":"75132_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41392-024-01872-7","volume":"9","author":"P Zhou","year":"2024","unstructured":"Zhou, P., Du, X., Jia, W., Feng, K. & Zhang, Y. Engineered extracellular vesicles for targeted reprogramming of cancer-associated fibroblasts to potentiate therapy of pancreatic cancer. Signal Transduct. Target Ther. 9, 151 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"75132_CR23","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ccell.2024.02.002","volume":"42","author":"H Zheng","year":"2024","unstructured":"Zheng, H. et al. PDGFR\u03b1(+)ITGA11(+) fibroblasts foster early-stage cancer lymphovascular invasion and lymphatic metastasis via ITGA11-SELE interplay. Cancer Cell 42, 682\u2013700.e612 (2024).","journal-title":"Cancer Cell"},{"key":"75132_CR24","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/cac2.12470","volume":"43","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. An HGF-dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis. Cancer Commun. 43, 1289\u20131311 (2023).","journal-title":"Cancer Commun."},{"key":"75132_CR25","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.cell.2014.01.040","volume":"156","author":"M Valiente","year":"2014","unstructured":"Valiente, M. et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 156, 1002\u20131016 (2014).","journal-title":"Cell"},{"key":"75132_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38841-7","volume":"14","author":"D Dervovic","year":"2023","unstructured":"Dervovic, D. et al. In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer. Nat. Commun. 14, 3150 (2023).","journal-title":"Nat. Commun."},{"key":"75132_CR27","doi-asserted-by":"crossref","unstructured":"Kimman, T., et al. Serpin B9 controls tumor cell killing by CAR T cells. J. Immunother. Cancer 11, e006364 (2023).","DOI":"10.1136\/jitc-2022-006364"},{"key":"75132_CR28","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1158\/0008-5472.CAN-19-2578","volume":"80","author":"C Tian","year":"2020","unstructured":"Tian, C. et al. Cancer cell-derived matrisome proteins promote metastasis in pancreatic ductal adenocarcinoma. Cancer Res. 80, 1461\u20131474 (2020).","journal-title":"Cancer Res."},{"key":"75132_CR29","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/0008-5472.CAN-16-2219","volume":"77","author":"SH Dzinic","year":"2017","unstructured":"Dzinic, S. H. et al. An essential role of maspin in embryogenesis and tumor suppression. Cancer Res. 77, 886\u2013896 (2017).","journal-title":"Cancer Res."},{"key":"75132_CR30","doi-asserted-by":"crossref","unstructured":"Rossi Sebastiano, M. et al. ACSL3-PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression. Sci. Adv. 6, eabb9200 (2020).","DOI":"10.1126\/sciadv.abb9200"},{"key":"75132_CR31","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s43018-023-00720-x","volume":"5","author":"YK Huang","year":"2024","unstructured":"Huang, Y. K. et al. Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy. Nat. Cancer 5, 400\u2013419 (2024).","journal-title":"Nat. Cancer"},{"key":"75132_CR32","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1158\/2159-8290.CD-24-0100","volume":"14","author":"KL Donahue","year":"2024","unstructured":"Donahue, K. L. et al. Oncogenic KRAS-dependent stromal interleukin-33 directs the pancreatic microenvironment to promote tumor growth. Cancer Discov. 14, 1964\u20131989 (2024).","journal-title":"Cancer Discov."},{"key":"75132_CR33","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1158\/2159-8290.CD-19-0958","volume":"10","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Regulatory T-cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis. Cancer Discov. 10, 422\u2013439 (2020).","journal-title":"Cancer Discov."},{"key":"75132_CR34","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.jcmgh.2022.02.016","volume":"13","author":"A Velez-Delgado","year":"2022","unstructured":"Velez-Delgado, A. et al. Extrinsic KRAS signaling shapes the pancreatic microenvironment through fibroblast reprogramming. Cell Mol. Gastroenterol. Hepatol. 13, 1673\u20131699 (2022).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"75132_CR35","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41422-019-0195-y","volume":"29","author":"J Peng","year":"2019","unstructured":"Peng, J. et al. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res. 29, 725\u2013738 (2019).","journal-title":"Cell Res."},{"key":"75132_CR36","doi-asserted-by":"crossref","unstructured":"Kirkpatrick, P., Graham, J. & Muhsin, M. Cetuximab. Nat Rev Drug Discov. 3, 549\u2013550 (2004).","DOI":"10.1038\/nrd1445"},{"key":"75132_CR37","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn4180","volume":"381","author":"X Lv","year":"2023","unstructured":"Lv, X. et al. Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Science 381, eabn4180 (2023).","journal-title":"Science"},{"key":"75132_CR38","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1158\/0008-5472.CAN-05-2448","volume":"66","author":"L Maggio-Price","year":"2006","unstructured":"Maggio-Price, L. et al. Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Res. 66, 828\u2013838 (2006).","journal-title":"Cancer Res."},{"key":"75132_CR39","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1016\/j.ccell.2024.08.001","volume":"42","author":"L Perelli","year":"2024","unstructured":"Perelli, L., Genovese, G. & Draetta, G. F. The KRAS mutational spectrum and its clinical implications in pancreatic cancer. Cancer Cell 42, 1494\u20131496 (2024).","journal-title":"Cancer Cell"},{"key":"75132_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41575-023-00840-w","volume":"21","author":"ZI Hu","year":"2024","unstructured":"Hu, Z. I. & O\u2019Reilly, E. M. Therapeutic developments in pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 21, 7\u201324 (2024).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"75132_CR41","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.trecan.2023.07.004","volume":"9","author":"NC Cheng","year":"2023","unstructured":"Cheng, N. C. & Vonderheide, R. H. Immune vulnerabilities of mutant KRAS in pancreatic cancer. Trends Cancer 9, 928\u2013936 (2023).","journal-title":"Trends Cancer"},{"key":"75132_CR42","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.ccell.2024.08.002","volume":"42","author":"CA McIntyre","year":"2024","unstructured":"McIntyre, C. A. et al. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. Cancer Cell 42, 1614\u20131629.e1615 (2024).","journal-title":"Cancer Cell"},{"key":"75132_CR43","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly, J. et al. Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer. Cancer Discov. 14, 2135\u20132161 (2024).","journal-title":"Cancer Discov."},{"key":"75132_CR44","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1158\/0008-5472.CAN-22-2585","volume":"83","author":"X Li","year":"2023","unstructured":"Li, X. et al. circFNDC3B accelerates vasculature formation and metastasis in oral squamous cell carcinoma. Cancer Res. 83, 1459\u20131475 (2023).","journal-title":"Cancer Res."},{"key":"75132_CR45","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/cac2.12527","volume":"44","author":"S Zhang","year":"2024","unstructured":"Zhang, S. et al. SERPINE2 promotes liver cancer metastasis by inhibiting c-Cbl-mediated EGFR ubiquitination and degradation. Cancer Commun. 44, 384\u2013407 (2024).","journal-title":"Cancer Commun."},{"key":"75132_CR46","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ccell.2019.03.002","volume":"35","author":"MT Blasco","year":"2019","unstructured":"Blasco, M. T. et al. Complete regression of advanced pancreatic ductal adenocarcinomas upon combined inhibition of EGFR and C-RAF. Cancer Cell 35, 573\u2013587.e576 (2019).","journal-title":"Cancer Cell"},{"key":"75132_CR47","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1158\/2159-8290.CD-23-1480","volume":"15","author":"Y Xu","year":"2025","unstructured":"Xu, Y. et al. Tumor-intrinsic kinome landscape of pancreatic cancer reveals new therapeutic approaches. Cancer Discov. 15, 346\u2013362 (2025).","journal-title":"Cancer Discov."},{"key":"75132_CR48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13045-024-01538-5","volume":"17","author":"AW Long","year":"2024","unstructured":"Long, A. W. et al. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma. J. Hematol. Oncol. 17, 20 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"75132_CR49","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1158\/1078-0432.CCR-23-1821","volume":"30","author":"V Ganju","year":"2024","unstructured":"Ganju, V. et al. Phase I\/IIa trial in advanced pancreatic ductal adenocarcinoma treated with cytotoxic drug-packaged, EGFR-targeted nanocells and glycolipid-packaged nanocells. Clin. Cancer Res. 30, 304\u2013314 (2024).","journal-title":"Clin. Cancer Res."},{"key":"75132_CR50","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1158\/2159-8290.CD-20-0519","volume":"11","author":"J Li","year":"2021","unstructured":"Li, J. et al. Epigenetic and transcriptional control of the epidermal growth factor receptor regulates the tumor immune microenvironment in pancreatic cancer. Cancer Discov. 11, 736\u2013753 (2021).","journal-title":"Cancer Discov."},{"key":"75132_CR51","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1200\/JCO.22.02630","volume":"41","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Nimotuzumab plus gemcitabine for K-Ras wild-type locally advanced or metastatic pancreatic cancer. J. Clin. Oncol. 41, 5163\u20135173 (2023).","journal-title":"J. Clin. Oncol."},{"key":"75132_CR52","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1093\/annonc\/mdx343","volume":"28","author":"B Schultheis","year":"2017","unstructured":"Schultheis, B. et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Ann. Oncol. 28, 2429\u20132435 (2017).","journal-title":"Ann. Oncol."},{"key":"75132_CR53","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1093\/annonc\/mdt270","volume":"24","author":"H Fensterer","year":"2013","unstructured":"Fensterer, H. et al. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Ann. Oncol. 24, 2576\u20132581 (2013).","journal-title":"Ann. Oncol."},{"key":"75132_CR54","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1200\/JCO.2009.25.8285","volume":"28","author":"CM Moinpour","year":"2010","unstructured":"Moinpour, C. M. et al. Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. J. Clin. Oncol. 28, 3611\u20133616 (2010).","journal-title":"J. Clin. Oncol."},{"key":"75132_CR55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1470-2045(07)70383-2","volume":"9","author":"S Cascinu","year":"2008","unstructured":"Cascinu, S. et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol. 9, 39\u201344 (2008).","journal-title":"Lancet Oncol."},{"key":"75132_CR56","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.20162024","volume":"214","author":"D \u00d6hlund","year":"2017","unstructured":"\u00d6hlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med 214, 579\u2013596 (2017).","journal-title":"J. Exp. Med"},{"key":"75132_CR57","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1016\/j.cell.2021.07.020","volume":"184","author":"K Koikawa","year":"2021","unstructured":"Koikawa, K. et al. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell 184, 4753\u20134771.e4727 (2021).","journal-title":"Cell"},{"key":"75132_CR58","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","volume":"160","author":"SF Boj","year":"2015","unstructured":"Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324\u2013338 (2015).","journal-title":"Cell"},{"key":"75132_CR59","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e3529 (2021).","journal-title":"Cell"},{"key":"75132_CR60","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329\u2013337.e324 (2019).","journal-title":"Cell Syst."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75132-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75132-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75132-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T01:01:51Z","timestamp":1786582911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75132-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75132"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75132-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"8317"}}